ADENURIC ADENURIC ADENURIC ADENURIC ZURIG ZURIG ZURIG ZURIG DEGOURIC DEGOURIC DEGOURIC DEGOURIC FEBORIC FEBORIC FEBORIC FEBORIC FEBUXA FEBUXA GOU-B GOU-B GOURIC GOURIC FEBULOUS FEBULOUS ULORA ULORA

Dose: 40 to 40 mg
Single Dose: 40 (40)
Frequency: 24 hourly
Route: PO
Instructions: This is the starting dose for hyperuricemia patients with gout. It can be taken with or without food.

. The Molecular Weight of Febuxostat is 316.38.

Febuxostat is contraindicated in conditions like Severe renal impairment,Severe liver impairment.

The severe or irreversible adverse effects of Febuxostat, which give rise to further complications include Fever, Neutropenia, Thrombocytopenic purpura, Angina, Slurred speech, Blurred vision, Irregular heart beat, Leukopenia.The symptomatic adverse reactions produced by Febuxostat are more or less tolerable and if they become severe, they can be treated symptomatically, these include Flatulence, Dizziness, Headache, Nausea, Vomiting, Diarrhea, Constipation, Abdominal pain, Dry mouth, Rashes, Gastritis, Mouth ulcers, Dyspepsia, Asthenia, Arthralgia, Muscle cramps, Edema, Dry mouth, Liver function abnormalities, Joint stiffness or swelling, dizziness, dyspepsia, gout flares.

Febuxostat is primarily indicated in conditions like Gout, Hyperuricemia.

No data regarding the interactions of Febuxostat was found.

Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tablet Store Between 15°C-30°C. Protect from Sunlight.

It may cause gout flare. Gout flare prophylaxis with NSAID or chlchicine for at least six months is recommended. Liver function test is recommended before initiating treatment and 2 and 4 minths following initiation of febuxostat and periodically thereafter.. Monitor signs and symptoms of Myocardial infarction (MI) and stroke. Use is not recommended in patients with a greatly increased rate of urate formation (eg, malignant disease and its treatment). Caution should be exercised when febuxostat is administered to nursing women. It is not recommended in less then 18 years of age. There are insufficient data in patients with severe renal impairment (Clcr less than 30 mL per min); therefore, caution should be exercised in these patients No studies have been conducted in patients with severe hepatic impairment; therefore, caution should be exercised in these patients